M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

被引：38

作者：

Ait-Khaled, M

Stone, C

Amphlett, G

Clotet, B

Staszewski, S

Katlama, C

Tisdale, M

机构：

[1] Hosp Germans Trias Pujoi, Barcelona, Spain

[2] Goethe Univ Frankfurt, D-6000 Frankfurt, Germany

[3] Hop La Pitie Salpetriere, Paris, France

来源：

AIDS | 2002年 / 16卷 / 12期

关键词：

D O I：

10.1097/00002030-200208160-00017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The resistance of HIV clinical isolates with or without M184V was analysed in relation to plasma HIV-1-RNA level and time on therapy. The number of thymidine analogue mutations (TAMs) was lower in isolates with M184V, this was independent of plasma HIV-1-RNA level and time on therapy for T215F/Y, D67N and L210W. This suggests a direct effect of M184V on the reduced selection of TAMs. Lamivudine use was significantly associated with lower median fold resistance to zidovudine and stavudine.

引用

收藏

页码：1686 / 1689

页数：4

相关论文

共 13 条

[1]

Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3

[2] The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis [J].

Götte, M ;

Arion, D ;

Parniak, MA ;

Wainberg, MA .

JOURNAL OF VIROLOGY, 2000, 74 (08) :3579-3585

[3]

GOTTE M, 1999, ANTIVIR THER, V4, P18

[4] Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].

Vahaboglu, H ;

Saribas, S ;

Akbal, H ;

Ozturk, R ;

Yucel, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270

[5] The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial [J].

Katlama, C ;

Clotet, B ;

Plettenberg, A ;

Jost, J ;

Arasteh, K ;

Bernasconi, E ;

Jeantils, V ;

Cutrell, A ;

Stone, C ;

Ait-Khaled, M ;

Purdon, S .

AIDS, 2000, 14 (07) :781-789

[6] Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients [J].

Kuritzkes, DR ;

Quinn, JB ;

Benoit, SL ;

Shugarts, DL ;

Griffin, A ;

Bakhtiari, M ;

Poticha, D ;

Eron, JJ ;

Fallon, MA ;

Rubin, M .

AIDS, 1996, 10 (09) :975-981

[7] POTENTIAL MECHANISM FOR SUSTAINED ANTIRETROVIRAL EFFICACY OF AZT-3TC COMBINATION THERAPY [J].

LARDER, BA ;

KEMP, SD ;

HARRIGAN, PR .

SCIENCE, 1995, 269 (5224) :696-699

[8] Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine [J].

Lennerstrand, J ;

Stammers, DK ;

Larder, BA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2144-2146

[9]

Masquelier B, 1999, ANTIVIR THER, V4, P69

[10] Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro [J].

Miller, MD ;

Anton, KE ;

Mulato, AS ;

Lamy, PD ;

Cherrington, JM .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :92-100